India Active Pharmaceutical Ingredients Market [2029]: Top Companies, Size, and Competitive Intelligence - TechSci Research

According to the TechSci Research report, “India Active Pharmaceutical Ingredients Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2020-2030,” the India Active Pharmaceutical Ingredients Market was valued at USD 13.60 Billion in 2023 and is anticipated to witness impressive growth with a CAGR of 8.30% through 2030.

Introduction

According to the TechSci Research report, “India Active Pharmaceutical Ingredients Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2020-2030,” the India Active Pharmaceutical Ingredients Market was valued at USD 13.60 Billion in 2023 and is anticipated to witness impressive growth with a CAGR of 8.30% through 2030.

Collaborations and partnerships among leading companies are driving the demand for Active Pharmaceutical Ingredients (APIs) in the pharmaceutical industry. These collaborations aim to merge the expertise of individual companies, bolstering their market position. Cost-effective manufacturing stands out as a primary driver of API demand, playing a pivotal role in keeping overall production costs low. This cost-effectiveness is instrumental in ensuring medication affordability, particularly for essential and chronic disease treatments.

 

Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on " India Active Pharmaceutical Ingredients Market”

 

Market Overview

Current Market Landscape

In a fiercely competitive pharmaceutical landscape, cost-effective API production enables manufacturers to offer competitive pricing for their drugs, significantly influencing market share and product adoption. Pharmaceutical companies encounter various cost pressures, including research and development expenses, regulatory compliance costs, and marketing expenditures. Therefore, cost-effective API manufacturing is crucial for maintaining healthy profit margins. Additionally, cost-effective APIs contribute to a steady and reliable supply of essential medications, thereby enhancing healthcare accessibility for a wider population, both domestically and globally. Given that many generic drugs rely on APIs, their affordability plays a pivotal role for patients and healthcare systems alike. Consequently, cost-effective API manufacturing is indispensable for producing generic versions of brand-name drugs.

 

Recent Trends

Rise in Generic Drug Demand

The burgeoning demand for generic drugs, both locally and globally, serves as a primary catalyst for the India API market. As cost-effective alternatives to branded medications, generic drugs are witnessing increasing popularity, with India emerging as a leading supplier of APIs for these pharmaceuticals. The relentless pursuit of affordable healthcare solutions is expected to sustain the upward trajectory of generic drug demand, thereby propelling the API market in India forward.

 

Government Initiatives

To fortify the domestic pharmaceutical industry, the Indian government has introduced several initiatives, such as the "Make in India" campaign and the facilitation of bulk drug parks. These endeavors are geared towards bolstering domestic API manufacturing capabilities, reducing reliance on imports, and positioning India as a global API production hub. Through supportive policies and government backing, an environment conducive to API manufacturers is created, fostering industry growth.

 

Technological Advancements

The adoption of advanced technologies in API manufacturing is another significant trend. Innovations in biotechnology, process optimization, and automation are enhancing production efficiency and quality. Companies are increasingly investing in research and development to develop new and improved APIs, addressing unmet medical needs and expanding their product portfolios.

 

Market Drivers

Cost-Effective Manufacturing

Cost-effective manufacturing stands out as a primary driver of API demand, playing a pivotal role in keeping overall production costs low. This cost-effectiveness is instrumental in ensuring medication affordability, particularly for essential and chronic disease treatments. In a fiercely competitive pharmaceutical landscape, cost-effective API production enables manufacturers to offer competitive pricing for their drugs, significantly influencing market share and product adoption. Pharmaceutical companies encounter various cost pressures, including research and development expenses, regulatory compliance costs, and marketing expenditures. Therefore, cost-effective API manufacturing is crucial for maintaining healthy profit margins. Additionally, cost-effective APIs contribute to a steady and reliable supply of essential medications, thereby enhancing healthcare accessibility for a wider population, both domestically and globally. Given that many generic drugs rely on APIs, their affordability plays a pivotal role for patients and healthcare systems alike. Consequently, cost-effective API manufacturing is indispensable for producing generic versions of brand-name drugs.

 

Increasing Prevalence of Chronic Diseases

The rising burden of infectious, genetic, and other chronic diseases such as cancer, diabetes, and neurological disorders is a key factor driving market growth. For instance, as per the 2022 statistics published by IDF, about 74 million people had diabetes in 2021 in India, and this number is estimated to reach 92.9 million by 2030. Thus, the high diabetic population in the country raises the company's focus on developing advanced and safe drugs that require a large amount of API, propelling the market growth.

 

Aging Population

The growing geriatric population is more prone to develop chronic diseases, such as cardiovascular and neurological diseases, arthritis, etc., due to weak immunity. Aging affects many cellular processes predisposing individuals to neurodegeneration, which is anticipated to increase market growth. For a study published in May 2021, about 18,896 people were screened for Parkinson's disease. The overall pervasiveness of the disease was almost 42.3 per 100,000. According to the same source, the prevalence over the age of 60 was 308.9 per 100,000, reflecting the trend of increasing disease predominance. Hence, the high burden of Parkinson's disorders among the elderly is anticipated to increase the demand for various therapeutic drugs and treatments, boosting the demand for APIs over market growth.

 

Emerging Disease Threats

Emerging disease threats pose challenges in the India Active Pharmaceutical Ingredients (API) market, impacting various facets of the pharmaceutical industry. The sudden onset of a new disease or epidemic can trigger heightened demand for APIs associated with treating or preventing the ailment. API manufacturers may need to swiftly ramp up production to meet this surge, presenting logistical and financial hurdles. Emerging disease threats have the potential to disrupt global supply chains, affecting the availability of essential raw materials and ingredients required for API production. This disruption can result in shortages and production delays, further complicating the situation. The pharmaceutical sector may encounter significant pressure to develop new drugs and vaccines in response to emerging diseases, placing strain on the resources and capabilities of API manufacturers. Collaborative efforts with pharmaceutical firms on R&D initiatives can stretch these manufacturers' capacities. Expediting the development and approval processes for drugs and APIs in response to emerging diseases entails navigating intricate regulatory pathways. Meeting regulatory standards and securing approvals within accelerated timelines poses significant challenges.

Market Segmentation

By Method of Synthesis

The India Active Pharmaceutical Ingredients Market can be segmented based on the method of synthesis into:

• Synthetic APIs: These are chemically synthesized and represent a significant portion of the market.
• Biotech APIs: Derived from biological sources, this segment is growing rapidly due to advancements in biotechnology.

By Source

The market can be segmented based on the source into:

• In-house: APIs manufactured within the pharmaceutical company.
• Outsourced: APIs produced by third-party manufacturers.

By Therapeutic Application

The market can be segmented based on therapeutic application into:

• Oncology Drugs: This segment is predominantly driven by the increasing prevalence of cancer and the demand for effective cancer treatments.
• Cardiovascular Drugs: Growing incidence of cardiovascular diseases drives this segment.
• Diabetes Drugs: High prevalence of diabetes in India boosts the demand for diabetes-related APIs.
• Neurological Drugs: Rising cases of neurological disorders contribute to the growth of this segment.
• Others: Including anti-infectives, respiratory drugs, and gastrointestinal drugs.

By Drug Type

The market can be segmented based on drug type into:

• Generic Drugs: This segment is anticipated to dominate the market, driven by the expiration of patents and the affordability of generic medications.
• Branded Drugs: While this segment is smaller, it continues to grow, driven by innovation and the introduction of new therapies.

By Region

The market can be segmented based on region into:

• North India: Dominates the market due to well-established infrastructure and pharmaceutical clusters.
• South India: Significant growth due to the presence of major pharmaceutical companies.
• West India: Growing pharmaceutical industry and infrastructure developments drive the market.
• East India: Emerging region with potential for significant growth in the API market.

Regional Insights

North India

North India dominates the India Active Pharmaceutical Ingredients Market, boasting well-established infrastructure and transportation networks, including robust road, rail, and air connectivity. These facilitate seamless movement of raw materials and finished products within and beyond the region. Notably, states like Himachal Pradesh host thriving pharmaceutical clusters, fostering a mutually beneficial ecosystem for the industry. Many pharmaceutical manufacturers in North India have made substantial investments to meet global quality standards and regulatory requirements, crucial for exporting APIs to international markets. North Indian pharmaceutical companies are also actively engaged in research and development endeavors, driving innovation and the creation of new APIs. Adopting an export-oriented approach, several companies in the region cater to international markets, solidifying North India's position in the global API trade. The region also benefits from a skilled and educated workforce, pivotal for pharmaceutical research, development, and manufacturing endeavors.

South India

South India is also a significant player in the API market, with states like Andhra Pradesh and Tamil Nadu being key contributors. The presence of major pharmaceutical companies and research institutions in these states fosters innovation and growth. Additionally, the region's infrastructure and transportation networks facilitate the efficient movement of goods, further enhancing its position in the market.

West India

West India, with states like Maharashtra and Gujarat, is another important region in the API market. The region is home to several leading pharmaceutical companies and has a well-developed infrastructure that supports the efficient production and distribution of APIs. Ongoing investments in research and development and infrastructure improvements are expected to drive further growth in this region.

East India

East India, though currently less dominant compared to other regions, is emerging as a potential growth area in the API market. The region's growing pharmaceutical industry and investments in infrastructure and research and development are expected to drive significant growth in the coming years.

Competitive Analysis

Major Players and Their Strategies

The India Active Pharmaceutical Ingredients Market is highly competitive, with several major companies operating in the sector. These companies are known for their extensive portfolios of APIs, innovative research and development efforts, and strong global presence. Some of the major companies in this market include:

• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries Limited
• Cipla Limited
• Lupin Limited
• Aurobindo Pharma Limited
• Aarti Drugs Ltd.
• IOL Chemicals and Pharmaceuticals Limited
• GSK plc

Download Free Sample Report

 

Read Blog- Top 10 Nutraceutical Companies in India : A Blend of Health and Innovation